Libourne, 2 nd .June 2016: Ceva Santé Animale announced today the purchase of Biovac Laboratories, a leading

manufacturer of autogeneous (bacterial) vaccines, allergy treatments and reagents based in Angers, France.

Biovac, like Ceva, has experienced double-digit growth for several years as veterinarians seek alternatives to control

bacterial conditions often now difficult to treat with “classic” antibiotherapy. The company has significant expertise in

microbiology, allowing it to provide custom-made solutions for veterinarians and their customers.

Ceva already offers custom vaccines to leading poultry and swine producers in other parts of the world. The strategy is

in line with Ceva’s stated AMR policy of putting the veterinarian back at the centre of the fight against microbial

diseases.  Auto vaccines are produced only after identification and diagnosis of the disease serotype by a qualified

veterinarian. In cases where a “standard vaccine” will not be effective, custom vaccines can be produced and

prescribed by the veterinarian in 4 to 5 weeks, creating an extremely reactive and precise service for livestock

producers.

Ceva’s Chairman & CEO, Dr. Marc Prikazsky said: “As a veterinarian, I know how disappointing it can be to make a

diagnosis and then not have the precise tool necessary to control the disease. Biovac provides an extraordinary service

to the veterinarians in France. Through this partnership, we will share all our expertise in vaccine production and new

technologies, so that together we can provide veterinarians in new markets with an even better service.”

________________________________________

About Ceva Santé Animale

Established in 1999, Ceva Santé Animale is a global veterinary group in the research, development, production and marketing

of pharmaceutical products and vaccines for companion and farm animals (ruminants, pigs, and poultry).

Present in over 110 countries, Ceva has averaged double digit growth since its creation to reach a turnover of € 857 million in

2015 (+ 12%). The company employs approximately 4,000 people worldwide, and is chaired by Dr. Marc Prikazsky.

www.ceva.com

Contact: Martin Mitchell, Group Communications Director - Tel. +33 5 57 55 40 80 - martin.mitchell@ceva.com